Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2024
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Cincytech
Deal Size : $7.7 million
Deal Type : Series B Financing
Invirsa Completes $7.7M Series B Financing
Details : The net financing will be used in advancing Invirsa's lead product candidate, INV-102, derived from a naturally occurring small molecule, in a series of Phase 2 studies in conditions including acute infectious keratoconjunctivitis, dry eye disease, and F...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 14, 2023
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Cincytech
Deal Size : $7.7 million
Deal Type : Series B Financing
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clenbuterol Hydrochloride,Nadolol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Clenbuterol Hydrochloride,Nadolol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2013
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2013
Lead Product(s) : Nadolol,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable